Novel genomic variants influencing methotrexate delayed clearance in pediatric patients with acute lymphoblastic leukemia

• Váldodahkkit: Jung Yoon Choi (Dahkki), Hoshik Kwon (Dahkki), Hyery Kim (Dahkki), Kyung Taek Hong (Dahkki), Youngeun Ma (Dahkki), Kyung-Nam Koh (Dahkki), Sunmin Yun (Dahkki), Keon Hee Yoo (Dahkki), Sang Hoon Song (Dahkki), Ho Joon Im (Dahkki), Ju Han Kim (Dahkki), Hyoung Jin Kang (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Frontiers Media S.A., 2024-11-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

BackgroundMethotrexate (MTX) is the primary drug used in the treatment of pediatric acute lymphoblastic leukemia (ALL). However, some patients exhibit delayed clearance of high-dose (HD) MTX, which induces severe nephrotoxicity, mucositis, hepatotoxicity, and neurotoxicity. We sought to identify rel...